Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

CDK4/6 Tumor, Abemaciclib, Paclitaxel

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04594005
Recruitment Status : Recruiting
First Posted : October 20, 2020
Last Update Posted : April 22, 2021
Sponsor:
Information provided by (Responsible Party):
Hyo Song Kim, Yonsei University

Brief Summary:

Cyclin D-dependent kinases (CDKs) are often activated in human cancer owing to various genetic and epigenetic events. This affects regulatory pathways, and it results in uncontrolled proliferation due to loss of checkpoint integrity. Most tumors show increased activity of CDKs, and this permits escape from senescence during the evolution of malignancy.

Among them, cyclin D-CDK4/6-INK4 pathway alterations accelerate G1 progression which provides proliferative and survival advantage to cancer. Therefore, preclinical data demonstrated inhibition of cyclin D-dependent kinase activity have therapeutic benefit. CDK4/6 controls entry into cell cycle progression by regulating Retinoblastoma protein (Rb). The majority of human cancers are known to retain wild-type Rb. In addition, CDK4 amplification and mutations also noted in several tumors. In Rb retained tumors, CDK 4/6 inhibitors reduced Rb phosphorylation and induced G1 arrest. In previous study, CDK4/6 inhibitor showed antitumor activities in Rb-positive breast and colon cancer cell lines. Rapid tumor regression was also noticed in mouse xenograft model. In CDK4 amplified sarcoma cell lines, knockdown of CDK4 inhibited cancer cell proliferation.

Cyclin D1 acts with CDK4 and CDK6 to phosphorylate Rb and promote cell-cycle progression, and CDK4/6 inhibitor might be effective for the patients with CCND1/2/3 amplification/mutation or CDK 4/6 amplification. Therefore, basket trial (NCT03310879) is ongoing for the patients with genomic alterations in CCND1, CDKN2A, or CDK4. Amplification/mutation of CCND1/2/3 and CDK4/6 occurs in approximately 15-30% of various solid tumors; sarcoma, GBM, melanoma, gem cell tumor, and gynecologic tumors Regarding the more potent synergistic effect, paclitaxel demonstrated a rationale for promising combination partner with CDK 4/6 inhibitors. In non-small cell lung cancer cell lines, synergistic anti-tumor activities were reported with paclitaxel combination. Corollary, we planned to conduct the phase Ib/II trial of abemaciclib and paclitaxel combination in CDK4/6 pathway activated tumors as one subgroup of multi-arms in ongoing basket trial.


Condition or disease Intervention/treatment Phase
Tumors Drug: abemaciclib+paclitaxel Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 36 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-label, Multi-center Phase IB/II Study of Abemaciclib With Paclitaxel for CDK4/6 Pathway Activated Tumors
Actual Study Start Date : February 25, 2021
Estimated Primary Completion Date : February 10, 2022
Estimated Study Completion Date : August 10, 2022

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: abemaciclib+paclitaxel Drug: abemaciclib+paclitaxel

Phase 1b: About 6-9 patients enrollment is expected at dose level 1, -1 and 2. Dose escalation will be preceded with 3 patients/cohort until the first DLT with 4 weeks' observation. The recommend phase 2 dose (RP2D) will be defined.

level1: abemaciclib 100mg bid, D1-28 / paclitaxel 80mg/m2, IV. D1, 8, 15 Q 4 weeks level-1: abemaciclib 50mg bid, D1-28 / paclitaxel 80mg/m2, IV. D1, 8, 15 Q 4 weeks level2: abemaciclib 150mg bid, D1-28 / paclitaxel 80mg/m2, IV. D1, 8, 15 Q 4 weeks

Phase2: At the RP2D dose level in phase I part, we will expand phase 2 study.





Primary Outcome Measures :
  1. overall response rate [ Time Frame: 8 weeks ]
  2. recommend phase 2 dose [ Time Frame: during 28 days after 1st dose ]
    to find the recommend phase 2 dose


Secondary Outcome Measures :
  1. adverse event [ Time Frame: 1 week ]
  2. disease control rate [ Time Frame: 8 weeks ]
  3. progression free survival [ Time Frame: 8 weeks ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   19 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically or cytologically confirmed locally advanced or metastatic solid tumors, for which standard therapy proven to provide clinical benefit no longer

    • CDK4/6 activated tumors on next-generation sequencing or FISH (fluorescence in situ hybridization) analyses

      - CCND1, 2, or 3 high-level amplification, CCND1 mutation, or a CCND1 splice variant expected to lead to nuclear retention of cyclin D1 protein

      - CDK4 or CDK6 high-level amplification

      • ECOG performance status of 0 to 1

        • ≥ 19 years of age

          • Subjects with measurable or evaluable disease ⑥ Subjects who meet the following criteria: - Absolute neutrophil count (ANC) ≥ 1000 /µL (*ANC = Neutrophil segs + Neutrophil bands) - Platelet count ≥ 75,000/ µL - Serum creatinine < 1.5 x upper limit of normal (ULN)

            • AST (SGOT) and ALT (SGPT) < 3 x upper limit of normal (ULN) (If there is Liver Metastasis < 5 x upper limit of normal (ULN))
            • Total bilirubin < 1.5 x upper limit of normal (ULN)

              • Provision of written informed consent prior to any study procedure

Exclusion Criteria:

  • Any unresolved chronic toxicity greater than CTC grade 2 from previous anticancer therapy.

    • Any previous chemotherapy or immunotherapy within 2 weeks or at least 3-5 half-lives for previous chemo/immunotherapy whichever is longer.

      • Any major operation or irradiation within 2 weeks of baseline disease assessment

        • Any clinically significant gastrointestinal abnormalities which may impair intake or absorption of the study drug

          • Previously abemaciclib-exposed patients

            ⑥ Subjects with symptomatic central nervous system (CNS) metastases who are neurologically unstable or have required increasing doses of steroids within the 2 weeks prior to study entry to manage CNS symptoms

            ⑦ Other co-existing malignancies or malignancies diagnosed within the last 3 years with the exception of basal cell carcinoma, thyroid cancer or cervical cancer in situ.

            ⑧ Subjects with an uncontrolled major cardiovascular disease (including AMI within 12 months, unstable angina within 6 months, over NYHA class III congestive heart failure, congenital long QT syndrome, 2° or more AV Block and uncontrolled hypertension)

            ⑨ Active infection including hepatitis B, hepatitis C

            ⑩ Pregnant or lactating female


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04594005


Contacts
Layout table for location contacts
Contact: Hyo Song Kim, MD 82-2-2228-8124 hyosong77@yuhs.ac

Locations
Layout table for location information
Korea, Republic of
Severance Hospital Recruiting
Seoul, Korea, Republic of, 03722
Contact: Hyo Song Kim, Ph.D       hyosong77@yuhs.ac   
Sponsors and Collaborators
Yonsei University
Layout table for additonal information
Responsible Party: Hyo Song Kim, Principal Investigator, Yonsei University
ClinicalTrials.gov Identifier: NCT04594005    
Other Study ID Numbers: 4-2020-0091
First Posted: October 20, 2020    Key Record Dates
Last Update Posted: April 22, 2021
Last Verified: April 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Paclitaxel
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action